Details

Autor(en) / Beteiligte

• Thijs, Lutgarde
• Asayama, Kei
• Maestre, Gladys E.
• Hansen, Tine W.
• Buyse, Luk
• Wei, Dong-Mei
• Melgarejo, Jesus D.
• Brguljan-Hitij, Jana
• Cheng, Hao-Min
• de Souza, Fabio
• Gilis-Malinowska, Natasza
• Kawecka-Jaszcz, Kalina
• Mels, Carina
• Mokwatsi, Gontse
• Muxfeldt, Elisabeth S.
• Narkiewicz, Krzysztof
• Odili, Augustine N.
• Rajzer, Marek
• Schutte, Aletta E.
• Stolarz-Skrzypek, Katarzyna
• Tsai, Yi-Wen
• Vanassche, Thomas
• Vanholder, Raymond
• Zhang, Zhen-Yu
• Verhamme, Peter
• Kruger, Ruan
• Mischak, Harald
• Staessen, Jan A.

Titel

Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol

Ist Teil von

• Blood pressure, 2021-09, Vol.30 (5), p.269-281

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Hypertension and diabetes cause chronic kidney disease (CKD) and diastolic left ventricular dysfunction (DVD) as forerunners of disability and death. Home blood pressure telemonitoring (HTM) and urinary peptidomic profiling (UPP) are technologies enabling prevention. UPRIGHT-HTM (Urinary Proteomics Combined with Home Blood Pressure Telemonitoring for Health Care Reform [NCT04299529]) is an investigator-initiated 5-year clinical trial with patient-centred design, which will randomise 1148 patients to be recruited in Europe, sub-Saharan Africa and South America. During the whole study, HTM data will be collected and freely accessible for patients and caregivers. The UPP, measured at enrolment only, will be communicated early during follow-up to 50% of patients and their caregivers (intervention), but only at trial closure in 50% (control). The hypothesis is that early knowledge of the UPP risk profile will lead to more rigorous risk factor management and result in benefit. Eligible patients, aged 55-75 years old, are asymptomatic, but have ≥5 CKD- or DVD-related risk factors, preferably including hypertension, type-2 diabetes, or both. The primary endpoint is a composite of new-onset intermediate and hard cardiovascular and renal outcomes. Demonstrating that combining UPP with HTM is feasible in a multicultural context and defining the molecular signatures of early CKD and DVD are secondary endpoints. The expected outcome is that application of UPP on top of HTM will be superior to HTM alone in the prevention of CKD and DVD and associated complications and that UPP allows shifting emphasis from treating to preventing disease, thereby empowering patients.